Summary
Boston Scientific Corporation (BSX) reported its financial results for the third quarter and the first nine months of 2020, a period significantly impacted by the COVID-19 pandemic. The company experienced a decline in net sales for both periods, primarily due to the postponement of elective and semi-emergent medical procedures. Despite the revenue decrease, BSX took proactive cost-reduction measures and maintained a strong liquidity position. Significant charges related to litigation, intangible asset impairments, and other restructuring items impacted reported net income, leading to a net loss for the third quarter and a net loss for the nine-month period. However, when excluding these non-recurring items, the company reported adjusted net income, demonstrating resilience in its core operations. BSX also managed its debt effectively and secured its credit facilities. The company's outlook remains focused on navigating the ongoing pandemic while continuing to invest in innovation and long-term growth.
Financial Highlights
50 data points| Revenue | $2.66B |
| Cost of Revenue | $869.00M |
| Gross Profit | $1.79B |
| SG&A Expenses | $984.00M |
| Operating Expenses | $2.00B |
| Operating Income | -$205.00M |
| Interest Expense | $86.00M |
| Net Income | -$155.00M |
| EPS (Basic) | $-0.12 |
| EPS (Diluted) | $-0.12 |
| Shares Outstanding (Basic) | 1.43B |
| Shares Outstanding (Diluted) | 1.43B |
Key Highlights
- 1Net sales for the third quarter of 2020 decreased by 1.8% to $2.659 billion compared to the prior year, with an 8.0% decrease for the first nine months to $7.204 billion, largely attributed to the impact of COVID-19 on medical procedures.
- 2The company reported a net loss of $155 million ($0.12 per diluted share) for the third quarter of 2020, compared to a net income of $126 million ($0.09 per diluted share) in the prior year. For the nine months ended September 30, 2020, the net loss was $292 million ($(0.22) per diluted share), compared to a net income of $704 million ($0.50 per diluted share) in the prior year.
- 3Significant charges, including $219 million in intangible asset impairment charges in Q3 2020 and $260 million in litigation-related charges in Q3 2020, heavily impacted reported net income.
- 4Excluding these special charges, adjusted net income available to common stockholders was $530 million ($0.37 per diluted share) for Q3 2020 and $1.040 billion ($0.73 per diluted share) for the nine months ended September 30, 2020.
- 5The company maintained a strong liquidity position, with cash and cash equivalents of $2.022 billion as of September 30, 2020, and had access to its full $2.750 billion revolving credit facility.
- 6BSX implemented cost-reduction initiatives, including temporary employee compensation adjustments and reduced discretionary spending, to mitigate the impact of the pandemic.
- 7The Peripheral Interventions segment showed strong growth with a 16.1% increase in net sales for Q3 2020, driven by the BTG acquisition's integration and growth in the Interventional Oncology franchise.